Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupting microglia-specific regulatory elements, reflecting microglial dysfunction as a central AD pathogenic mechanism. Credible sets at loci with known effector genes (APOE, TREM2, PLCG2) will be smaller (<10 variants) due to stronger functional constraints, while novel loci will have larger sets requiring integration with epigenomic data to prioritize causal variants. The highest
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.86
Evidence
0.72
Novelty
0.68
Feasibility
0.85
Impact
0.00
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.00
KG Connect
0.53
Score Breakdown
Dimension
AD fine-mapping identifies cau
Mechanistic
0.860
Evidence
0.720
Novelty
0.680
Feasibility
0.850
Impact
0.000
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.000
KG Connect
0.533
Evidence
AD fine-mapping identifies causal variants in microglia-spec